Navigation Links
Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Date:12/7/2008

TOKYO and EDISON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

The Phase III global study, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF TIMI 48), will compare DU-176b with warfarin in preventing stroke and systemic embolic events (SEE) in patients with atrial fibrillation. The primary safety assessment will be the incidence of bleeding.

Results from a recently presented Phase II safety study showed that the incidence of major and clinically relevant non-major bleeding events reported in the once-daily DU-176b treatment groups (30 mg or 60 mg) was similar to that in the warfarin-treated patient group. The incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg), compared to the warfarin group. The Phase III study will therefore randomize approximately 16,500 patients to one of three treatment groups: 30 mg DU-176b once daily, 60 mg DU-176b once daily, or warfarin. Those randomized to warfarin will be dosed once daily with dose adjustments to maintain International Normalized Ratio (INR) between 2.0 and 3.0.

This is an event-driven, Phase III, multinational, randomized, double-blind study with sites in North and South America, Africa, Asia, Europe, Australia and New Zealand. The expected median treatment duration of the study is 24 months; Daiichi Sankyo expects the study to conclude in the first half of 2012.

"There is a need for a safe and effective option for the prevention of clotting or stroke in patients with atrial fibrillation other than the current standard of care, warfarin, which
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
8. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MENLO PARK, Calif. , Aug. 27, ... developer of advanced cancer therapeutics , will be ... Rodman & Renshaw Global Investment Conference, sponsored by ... place Tuesday, September 9th at 2:55 p.m. EDT in ... York Palace Hotel in New York City ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Orthopedic Soft Tissue ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic Soft ... mass of cells that connect, support, or surround ... tissues such as tendons, ligaments, cartilage, fascia, and ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
Breaking Medicine Technology:DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2
(Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... filed in U.S. courts on behalf of women who ... uterine morcellation, Bernstein Liebhard LLP reports. According to court ... on August 18th in the U.S. District Court, Northern ... patient who claims the use of a power morcellator ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 Picture, ... no, not Holmes and Watson but more of a Mr. ... Glenn Davis, in terms of personalities and world view. This ... The University of Texas at Austin, and Mr. Outside was ... professor’s family physician, his new girlfriend, and a gaggle of ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 When Jagger was ... call from his mother; one that he credits as one ... His mom had news that she could set him up ... people with disabilities. Jagger took that job, and he has ... Throughout these past two decades, he also worked in school ...
(Date:8/27/2014)... 2014 The newest Abington Health ... September 8, 2014. This new 15,000 square foot, $5 ... primary care practices and walk-in laboratory services. ... exciting endeavor for Abington Health as the healthcare landscape ... Health. “Establishing a location in Lower Gwynedd allows us ...
(Date:8/27/2014)... By Amy Norton ... -- People who take part in clinical trials of new ... typical heart patient, a new study confirms. Experts said ... of the American Medical Association , aren,t surprising -- but ... trials are enrolling a more select patient population that is ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:UW Rankin Self-Publishes Debut Novel, Sublimity: Perchance to Dream, A Speculative Science Mystery 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 2Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 3Health News:Fitness on the Go Expands into Liberty Village, City Place and Harbourfront Communities 4Health News:Abington Health Opens New Health Center in Lower Gwynedd 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3
... , , , ... 22, 2010 , Forterus, Inc. (Pink Sheets: FTER) announced its results ... CEO, stated, "This has been a transformational year for Forterus and ... believe we have a strong foundation from which to grow our ...
... , Jan. 23 Following the announced end of search ... international aid agency Oxfam said: , "The end of search and rescue ... the survivors is the priority now. , "Hundreds of thousands who lost ... latrines to contain the spread of disease. They need shelter and simple ...
... less, MRI scans show , SATURDAY, Jan. 23 (HealthDay News) ... have less activity in the frontal lobes of their brain, ... activate a portion of your frontal lobes, the more accurate ... yourself as desirable or better than your peers, the less ...
... (PHILADELPHIA) People who are in car crashes ... other injuries at nights or on weekends do not ... disparities as patients who suffer heart attacks, strokes, cardiac ... according to new research from the University of Pennsylvania ...
... 2010 A new American Cancer Society report outlines 21 challenges ... of issues to be addressed and expertise needed to reduce ... low- and middle-income nations that are the target of the ... will appear in the January/February issue of CA: A ...
... is one of the ten most disabling diseases in the ... financial burden on health services as average life expectancy increases. ... nearly 27 million Americans or 12.1% of the adult population ... 2001 study showed that the disease costs US health services ...
Cached Medicine News:Health News:Forterus Announces Fiscal Year 2009 Financial Results 2Health News:Forterus Announces Fiscal Year 2009 Financial Results 3Health News:Forterus Announces Fiscal Year 2009 Financial Results 4Health News:Oxfam Relief Efforts Continue In Haiti 2Health News:Self-Image Linked to Activity in Frontal Lobe of Brain 2Health News:Trauma patients safe from mortality risks associated with so-called 'weekend effect' 2Health News:Trauma patients safe from mortality risks associated with so-called 'weekend effect' 3Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Cartilage repair can improve life, ease burden on health services 2
This double-up gel dryer system, 200-240 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 230 V, 50 Hz gel drying oven....
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
Capable of producing up to 500 volts and 500 milliamps, this power supply is ideal for PAGE, SDS-PAGE, DNA or RNA submarine gels as well as all types of small format transfer apparatus....
Medicine Products: